2020

16 December, 2020 R

Lipidor signs cooperation agreement with contract manufacturer to offer licensees the opportunity for GMP production

STOCKHOLM, Sweden, 16 December 2020 – Lipidor AB (Nasdaq First North:LIPI) announced today that the Company has signed a new cooperation agreement with Aurena Laboratories… Read more

27 November, 2020 R

Lipidor presents Nomination Committee

Stockholm, 27 November 2020 – Lipidor’s Annual General Meeting on 11[th] June 2020, adopted an instruction regarding the appointment of the Nomination Committee. Read more

19 November, 2020 R

Lipidor publishes interim report for Q3 2020

STOCKHOLM, 19 August 2020: Today, Lipidor AB publishes its interim report for the period July – September 2020. The quarterly report is available on the… Read more

01 October, 2020

Lipidor strengthens management through strategic hire

Stockholm, 1 October 2020: Lipidor AB (Nasdaq First North: LIPI) today announces that the company is strengthening its management team through the recruitment of Anders… Read more

30 September, 2020 R

Lipidor announces positive outcome of feasibility study for development of topical medical cannabis products based on the company's AKVANO® technology

Stockholm, 30 September 2020 - Lipidor AB (Nasdaq First North:LIPI) today announces a positive outcome of the feasibility study into the development of topical medicinal… Read more

18 August, 2020 R

Correction: Lipidor publishes interim report for H1 2020

In the last press release, Lipidor published that the information and interim report was such that Lipidor is required to publish under the EU Market… Read more

18 August, 2020 R

Lipidor publishes interim report for H1 2020

Today, Lipidor AB publishes its interim report for the period January - June 2020. The quarterly report is available on the company's website lipidor.se (https://lipidor.se/investors/financial-reports/interim-reports/) and… Read more

11 August, 2020 R

Resolutions from Lipidor’s Extraordinary General Meeting

Today, 11 August 2020, Lipidor AB (publ) (the “Company” or “Lipidor”) held an extraordinary general meeting (“EGM”) in Solna, Sweden. The EGM resolved upon, inter… Read more

07 July, 2020 R

Lipidor signs agreement with CRO for implementation of Phase III clinical study of drug candidate AKP-02 against Psoriasis

Lipidor AB (Nasdaq First North: LIPI) today announced an agreement with Cadila Pharmaceuticals, a leading Indian pharmaceutical company with extensive CRO capacity, to conduct a… Read more

07 July, 2020 R

Lipidor AB (publ) announces subsidiary Emollivet AB’s recruitment of Stina Linge as CEO

Lipidor AB ("Lipidor") today announces that the subsidiary Emollivet AB ("Emollivet") has recruited Stina Linge as CEO. Stina Linge joins Emollivet from her most recent… Read more

30 June, 2020 R

NOTICE OF EXTRAORDINARY GENERAL MEETING OF LIPIDOR AB (publ)

The shareholders of Lipidor AB (publ) (the "Company") are hereby invited to attend an Extraordinary General Meeting on August 11, 2020 at 11:00 a.m. CET.… Read more

30 June, 2020 R

Lipidor AB (publ) formalizes relationship with subsidiary Emollivet AB through license agreement and proposes financing of subsidiary

Lipidor AB ("Lipidor" or the “Company") and its subsidiary Emollivet AB ("Emollivet") have formalized the relationship by entering into a licence agreement that regulates the… Read more

11 June, 2020 R

Resolutions from Annual General Meeting, 11 June 2020

Lipidor AB held its Annual General Meeting (“AGM”) today, on the 11 June 2020, in Solna. The AGM elected the Chairman-elect of the Board, Fredrik… Read more

19 May, 2020 R

Lipidor publishes interim report for Q1 2020

Today, Lipidor AB publishes its interim report for the period January - March 2020. The Q1 report is available on the company's website lipidor.se (https://www.lipidor.se/) and… Read more

11 May, 2020 R

NOTICE OF ANNUAL GENERAL MEETING OF LIPIDOR AB (publ)

The shareholders of Lipidor AB (publ) are hereby invited to attend the Annual General Meeting (the “AGM”) to be held on June 11, 2020 at… Read more

07 May, 2020 R

Lipidor presents updated project plan – initiates Phase III study of AKP02 in-house

In light of the company's successful Phase III study of calcipotriol spray (AKP01) against mild to moderate plaque psoriasis and subsequent discussions with pharmaceutical companies,… Read more

04 March, 2020

New disinfection spray from Lipidor and Aurena Laboratories

In connection with the ongoing outbreak of Covid-19, caused by the new coronavirus, demand for disinfectants has snowballed and many products have suffered from supply… Read more

25 February, 2020 R

Lipidor AB re-publishes year-end report for 2019

Yesterday, 24[ ]February at 4.59pm (CET), Lipidor AB (publ) published our year-end report for 2019 one day earlier than announced. We hereby re-publish the year-end report 2019 on the date and time… Read more

24 January, 2020 R

Lipidor announces positive topline results of AKP01 Phase III clinical study using calcipotriol spray against psoriasis

Lipidor AB (Nasdaq First North: LIPI) today reports positive topline results of its AKP01 Phase III clinical study, using calcipotriol spray against mild to moderate… Read more

02 January, 2020

Lipidor AB (publ): The Knowledge Foundation funds collaborative project to study the effects of drug formulations on the skin barrier

Lipidor AB (Nasdaq First North: LIPI), in collaboration with Malmö University, MediGelium AB, Larodan AB and ERCO Pharma AB, has been awarded a research grant… Read more

Load more
16 December, 2020 R

Lipidor signs cooperation agreement with contract manufacturer to offer licensees the opportunity for GMP production

STOCKHOLM, Sweden, 16 December 2020 – Lipidor AB (Nasdaq First North:LIPI) announced today that the Company has signed a new cooperation agreement with Aurena Laboratories… Read more

27 November, 2020 R

Lipidor presents Nomination Committee

Stockholm, 27 November 2020 – Lipidor’s Annual General Meeting on 11[th] June 2020, adopted an instruction regarding the appointment of the Nomination Committee. Read more

19 November, 2020 R

Lipidor publishes interim report for Q3 2020

STOCKHOLM, 19 August 2020: Today, Lipidor AB publishes its interim report for the period July – September 2020. The quarterly report is available on the… Read more

30 September, 2020 R

Lipidor announces positive outcome of feasibility study for development of topical medical cannabis products based on the company's AKVANO® technology

Stockholm, 30 September 2020 - Lipidor AB (Nasdaq First North:LIPI) today announces a positive outcome of the feasibility study into the development of topical medicinal… Read more

18 August, 2020 R

Correction: Lipidor publishes interim report for H1 2020

In the last press release, Lipidor published that the information and interim report was such that Lipidor is required to publish under the EU Market… Read more

18 August, 2020 R

Lipidor publishes interim report for H1 2020

Today, Lipidor AB publishes its interim report for the period January - June 2020. The quarterly report is available on the company's website lipidor.se (https://lipidor.se/investors/financial-reports/interim-reports/) and… Read more

11 August, 2020 R

Resolutions from Lipidor’s Extraordinary General Meeting

Today, 11 August 2020, Lipidor AB (publ) (the “Company” or “Lipidor”) held an extraordinary general meeting (“EGM”) in Solna, Sweden. The EGM resolved upon, inter… Read more

07 July, 2020 R

Lipidor signs agreement with CRO for implementation of Phase III clinical study of drug candidate AKP-02 against Psoriasis

Lipidor AB (Nasdaq First North: LIPI) today announced an agreement with Cadila Pharmaceuticals, a leading Indian pharmaceutical company with extensive CRO capacity, to conduct a… Read more

07 July, 2020 R

Lipidor AB (publ) announces subsidiary Emollivet AB’s recruitment of Stina Linge as CEO

Lipidor AB ("Lipidor") today announces that the subsidiary Emollivet AB ("Emollivet") has recruited Stina Linge as CEO. Stina Linge joins Emollivet from her most recent… Read more

30 June, 2020 R

NOTICE OF EXTRAORDINARY GENERAL MEETING OF LIPIDOR AB (publ)

The shareholders of Lipidor AB (publ) (the "Company") are hereby invited to attend an Extraordinary General Meeting on August 11, 2020 at 11:00 a.m. CET.… Read more

30 June, 2020 R

Lipidor AB (publ) formalizes relationship with subsidiary Emollivet AB through license agreement and proposes financing of subsidiary

Lipidor AB ("Lipidor" or the “Company") and its subsidiary Emollivet AB ("Emollivet") have formalized the relationship by entering into a licence agreement that regulates the… Read more

11 June, 2020 R

Resolutions from Annual General Meeting, 11 June 2020

Lipidor AB held its Annual General Meeting (“AGM”) today, on the 11 June 2020, in Solna. The AGM elected the Chairman-elect of the Board, Fredrik… Read more

19 May, 2020 R

Lipidor publishes interim report for Q1 2020

Today, Lipidor AB publishes its interim report for the period January - March 2020. The Q1 report is available on the company's website lipidor.se (https://www.lipidor.se/) and… Read more

11 May, 2020 R

NOTICE OF ANNUAL GENERAL MEETING OF LIPIDOR AB (publ)

The shareholders of Lipidor AB (publ) are hereby invited to attend the Annual General Meeting (the “AGM”) to be held on June 11, 2020 at… Read more

07 May, 2020 R

Lipidor presents updated project plan – initiates Phase III study of AKP02 in-house

In light of the company's successful Phase III study of calcipotriol spray (AKP01) against mild to moderate plaque psoriasis and subsequent discussions with pharmaceutical companies,… Read more

25 February, 2020 R

Lipidor AB re-publishes year-end report for 2019

Yesterday, 24[ ]February at 4.59pm (CET), Lipidor AB (publ) published our year-end report for 2019 one day earlier than announced. We hereby re-publish the year-end report 2019 on the date and time… Read more

24 January, 2020 R

Lipidor announces positive topline results of AKP01 Phase III clinical study using calcipotriol spray against psoriasis

Lipidor AB (Nasdaq First North: LIPI) today reports positive topline results of its AKP01 Phase III clinical study, using calcipotriol spray against mild to moderate… Read more

Load more